BIO Comments on USTR Objectives for U.S. – Japan Trade Agreement
December 12, 2018
BIO welcomes progress made in recent U.S. bilateral trade agreements, in particular with Australia and Korea, to require transparency and accountability of foreign government pricing and reimbursement of biopharmaceuticals, to ensure market access and reward for innovation. BIO believes that to ensure that U.S. trading partners are allowing fair, non-discriminatory access to new medicines, and shouldering a fair share of the costs of innovation, that any modern trade agreement, including a U.S-Japan agreement should build on these provisions.
Download Full Comments Below
BIO Negotiations Objectives - US-Japan Trade Final 112618
Dear Mr. Thune, Mr. Schumer, Mr. Johnson, and Mr. Jeffries:As President and CEO of the Biotechnology Innovation Organization (BIO), as a father and entrepreneur whose family is here today because of biotech innovation, and on behalf of the more than…
BIO welcomes progress made in recent U.S. bilateral trade agreements, in particular with Australia and Korea, to require transparency and accountability of foreign government pricing and reimbursement of biopharmaceuticals, to ensure market access and reward for innovation. BIO believes that to ensure that U.S. trading partners are allowing fair, non-discriminatory access to new medicines, and shouldering a fair share of the costs of innovation, that any modern trade agreement, including a U.S-Japan agreement should build on these provisions.